Table 2 Key events in the discovery of the first two waves of epigenetic drugs
From: The timeline of epigenetic drug discovery: from reality to dreams
| Â | DNA methyltransferase inhibitors |
1964 | Azacitidine and decitabine synthesis |
1967 | Azacitidine enters clinical trials |
1980 | Azacitidine and decitabine identified as DNMT inhibitors |
1980 | Decitabine enters clinical trials |
2004 | Azacitidine FDA approval |
2006 | Decitabine FDA approval |
| Â | Histone deacetylase inhibitors |
1971 | DMSO reported as differentiation agent |
1976 | Bisamide precursor to SAHA (vorinostat) reported as differentiation agent |
1990 | Trichostatin A identified as HDAC inhibitor |
1990 | Romidepsin reported as a natural product |
1996 | Vorinostat synthesis |
1997 | Romidepsin enters clinical trials |
1998 | Vorinostat and romidepsin identified as HDAC inhibitors |
2000 | Vorinostat enters clinical trials |
2006 | Vorinostat FDA approval |
2009 | Romidepsin FDA approval |
2014 | Belinostat FDA approval |
2015 | Panobinostat FDA approval |
2015 | Chidamide China’s FDA approval |